Galaxy Biomedical Investment Co., Ltd. (SZSE:000806) signed an equity transfer agreement to acquire 5.6% stake in Yunnan Hansu Biological Technology Co., Ltd. from Hanma Investment Group Co., Ltd. for CNY 30 million on April 26, 2018. Upon completion, Galaxy Biomedical Investment Co., Ltd. will hold 5.6% stake and Hanma Investment Group Co., Ltd. will hold 74.5% stake in Yunnan Hansu Biological Technology Co., Ltd. For the year ended December 31, 2017, Yunnan Hansu Biological Technology Co., Ltd. had total assets of CNY 88.4 million, net assets of CNY 79.3 million, operational profits of CNY 26.9 million and net profits of CNY 20.3 million. The transaction has been approved by the Board of Galaxy Biomedical Investment Co., Ltd. Galaxy Biomedical Investment Co., Ltd. (SZSE:000806) cancelled the acquisition of 5.6% stake in Yunnan Hansu Biological Technology Co., Ltd. from Hanma Investment Group Co., Ltd. on April 26, 2019.